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The aim of this study was to assess exercise test results and efficacy of therapy with a 
blocker (acebutolol) in ryanodine receptor type 2 (RyR2) mutation carriers with docu-
mented ventricular arrhythmias (VAs) and long-term follow-up. Twenty RyR2 mutation
carriers belonging to 8 families and regularly followed at our center were analyzed using a
study protocol involving electrocardiography, exercise tests off and on -blocker therapy,
2-dimensional echocardiography, and signal-averaged electrocardiography. Off-therapy
exercise testing triggered the onset of VAs at different heart rates (mean 132  13
beats/min) with various patterns that worsened while exercising and disappeared imme-
diately after stopping. The most severe VAs detected were nonsustained ventricular tachy-
cardia in 35% and ventricular couplets in 35%. In the remaining subjects single ventricular
premature beats were recorded. In 15% of patients single monomorphic ventricular pre-
mature beats were detected and identified to be linked to RyR2 mutations owing to the
presence of sudden deaths of their family members and subsequent family screening.
Acebutolol made the VAs disappear completely in 20% of subjects and decreased their
complexity in 50%, whereas it did not change VAs appreciably in 30% of patients with less
complex VAs. After 11  8 years of follow-up 2 patients developed syncope. In conclusion,
exercise testing was a fundamental tool for assessing the clinical phenotype and efficacy of
therapy in RyR2 mutation carriers and therapy with acebutolol led in most subjects to a
decreased complexity of the arrhythmic pattern or to complete suppression.
© 2012 Elsevier Inc.
(Am J Cardiol 2012;109:1015–1019)
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Open access under CC BY-NC-ND license.Ryanodine receptor type 2 (RyR2) has a pivotal role in
regulating excitation– contraction coupling and sinoatrial
node function.1– 4 RyR2 mutations alter channel activity
t adrenergic activation, increasing the likelihood of
pontaneous calcium release during diastole, which is the
asis for triggered and polymorphic ventricular arrhyth-
ias (VAs).5–8 The main clinical entity is the cat-
cholaminergic polymorphic ventricular tachycardia (VT),
highly malignant arrhythmogenic disorder prevalently
resent in a structurally normal heart, which is an important
ause of sudden death in children and young adults.9–18
Exercise triggers the onset of a broad spectrum of VAs that
progressively worsen, usually leading to a highly reproduc-
ible polymorphic or bidirectional VT that fades on stopping
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Open access under CC BY-NC-ND license.exercising.18–22 The aim of our study was to analyze exer-
cise test findings in a group of RyR2 mutation carriers
developing VAs while they were off and on -blocker
herapy and study the efficacy of a  blocker (acebutolol)
ver a lengthy follow-up.
ethods
From a cohort of 8 families (39 RyR2 mutation carriers)
e selected 20 patients who carried 7 different RyR2 mu-
ations, developed VAs during exercise testing, and were
eing monitored regularly. Silent mutation carriers (10 sub-
ects without VAs during follow-up) and subjects with in-
omplete follow-up (9 subjects) were excluded. Our pa-
ients were heterozygous for RyR2 mutations: 6 carried the
2386I, 6 the A2387P, 2 the Y2392C, 2 the A77V, 2 the
433P, 1 the R420W, and 1 the M4504I. All mutations have
een reported previously.9,12,17,23 Two patients were index
cases identified with exercise testing before participation
during a screening for competitive sports, and the remaining
subjects were discovered through family screening because
of a positive family history of sudden death during effort
or emotion (13 subjects, mean age 19  5.7 years). All
ubjects underwent electrocardiography, exercise testing,
www.ajconline.org
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phy with Doppler study.
The cycling exercise test was done using a 25-W  2
rotocol that assessed the first exercise tests performed off
nd on  blocker (within 1 month) and the last test per-
ormed on  blocker. Acebutolol, a  blocker with intrinsic
ympathicomimetic activity, was chosen because it was
sed since the beginning in all patients, produces less arte-
ial hypotension, and because of the good results on VAs
as continued throughout the follow-up. All exercise tests
ere performed until onset of muscular fatigue or appear-
nce of VT. Maximum heart rates (HRs) and workloads
ere recorded. The following features of VAs were ana-
yzed: HR and workload at onset of VAs; most frequent
entricular premature beat (VPB) morphologies; episodes
f ventricular bigeminy, ventricular couplets, VT, and cor-
esponding HR; and behavior of VAs after stopping exer-
ise. During the first exercise test off  blocker we also
onsidered the mode of onset of VAs (coupling interval and
orphology of the first VPB and corrected QT interval of the
ast sinus beat preceding onset of arrhythmia). Features of VAs
nder maximum exercising workload were recorded.
All continuous variables were expressed as mean  SD.
tudent’s paired and unpaired t tests were used to compare
ormally distributed data and Kruskal–Wallis test was used
n all other cases. Chi-square test was used to compare
oncontinuous variables expressed as proportions.
esults
Twenty patients (8 men, 12 women) were analyzed.
heir age at the time of baseline exercise tests was 27  13
ears and their age at the last test was 38  13 years, so the
Table 1
Comparison between exercise stress test off therapy and on therapy (at fir
Variable Off Therapy
Dosage (mg) 0
Maximum heart rate (beats/min) 154  17
Maximum heart rate predicted by age (mean
percentage)
80  8
Maximum workload (W) 140  58
Heart rate threshold of arrhythmias (beats/min) 132  13
Workload at arrhythmia onset (W) 111  42
Heart rate at arrhythmia disappearance (beats/min) 143 17
Onset of ventricular bigeminy (beats/min) 144  15
Patients with ventricular bigeminy (%) 15 (75%)
Patients without arrhythmias (%) 0 (0%)
Patients with ventricular couplets (%) 14 (70%)
Patients with nonsustained ventricular tachycardia (%) 7 (35%)
Patients with polymorphic arrhythmias (%) 17 (85%)
Patients with prevalent left bundle branch block
morphology (%)§
10 (50%)
Patients with prevalent right bundle branch block
morphology (%)§
7 (35%)
* First test off therapy versus first test on therapy.
† First test on therapy versus last test on therapy.
‡ First test off therapy versus last test on therapy.
§ For morphologies of ventricular arrhythmias, during the first exercis
discriminate a prevalent morphology, whereas during the 2 exercise tests oean follow-up was 11  8 years (range 2 to 27).Electrocardiography performed in the absence of therapy
as considered normal in all patients. Sinus bradycardia at
est was found in 30%. Corrected QT interval was normal
mean 415  24 ms). During follow-up 1 patient had a
rst-degree atrioventricular block and 1 a relatively short
T interval. Sinus bradycardia was recorded in another 2
atients. Follow-up electrocardiograms did not differ sig-
ificantly from baseline in the remaining patients. On
ignal-averaged electrocardiogram late potentials were pres-
nt in 4 subjects (20%) at the first assessment and at last
ollow-up.
Two-dimensional echocardiogram detected mild right
entricular dilation in 5 patients (25%) and 2 of them also
ad mild left ventricular dilation. One patient had right
entricular wall motion abnormalities (akinesia of the sub-
ricuspid region and basal free wall). These findings did not
hange significantly during follow-up. None of the patients
ulfilled the criteria for a definite diagnosis of arrhythmo-
enic right ventricular cardiomyopathy.24
For exercise testing off therapy the initiation, progres-
sion, and termination of VAs were studied (Table 1). Pa-
tients reached a maximum HR of 154  17 beats/min
(equivalent of 80  8% of maximum HR predicted for age)
and a maximum workload of 140  58 W. Mean HR at
onset of the first VPB was 132  13 beats/min (minimum
115 beats/min, maximum 156 beats/min) under a mean
workload of 111  42 W. The coupling interval of the first
VPB was 407  30 ms. The corrected QT interval of the
preceding sinus beat was 424  22 ms. The first VPB
revealed left bundle branch block or right bundle branch
block morphology. VPBs with left bundle branch block
morphology showed an inferior-axis deviation (75° to 105°)
ation and last follow-up)
t on Therapy Last on Therapy p Value
1* 2† 3‡
191  59 280  81 — 0.0007 —
133  13 134  14 0.00001 0.9 0.0003
69  6 73  5 0.00002 0.01 0.002
134  55 137  58 0.9 0.6 0.4
125  9 125  14 0.03 0.7 0.1
120  45 108  41 0.08 0.7 0.5
131  13 128  16 0.004 0.4 0.02
133  10 125  9 0.002 0.05 0.005
11 (55%) 8 (40%) 0.2 0.3 0.03
3 (15%) 4 (20%) 0.08 0.7 0.04
4 (20%) 1 (5%) 0.003 0.1 0.0001
0 (0%) 0 (0%) 0.006 1 0.006
6 (30%) 6 (30%) 0.001 1 0.001
13 (65%) 12 (60%) 0.3 0.7 0.5
3 (15%) 3 (15%) 0.1 1 0.1
patients presented polymorphic arrhythmias but it was not possible to
y it was not possible to discriminate a prevalent morphology in 1 subject.st evalu
Firs
e test 3in 7 subjects and left-axis deviation (30°) in 3 subjects.
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1017Arrhythmias and Conduction Disturbances/Exercise Test in RyR2 Mutation CarriersVPBs with right bundle branch block morphology showed
left- or right-axis deviation in 9 subjects and a normal axis
in 1. In 16 patients (80%) VAs began as monomorphic and
became polymorphic as exercise progressed. In 3 patients
(15%) VAs remained monomorphic during the entire exer-
cise test. Ventricular bigeminy occurred in 75%, appearing
at a mean HR of 144  15 beats/min (minimum 130
beats/min, maximum 175 beats/min). Predominantly poly-
morphic ventricular couplets occurred in 70%, appearing at
a mean HR of 145  15 beats/min (minimum 125 beats/
min, maximum 176 beats/min) and a workload of 129  51
. Polymorphic nonsustained VT was detected in 7 sub-
ects (35%), occurring at a mean HR of 158  16 beats/min
(minimum 140 beats/min, maximum 175 beats/min) with a
maximum ventricular rate of 191  28 beats/min. Two
subjects with nonsustained VT were index cases, and 5 were
found during cascade screening and had the N2386I muta-
tion. Under maximum workload the most severe VAs ob-
served were nonsustained VTs in 35% and couplets in 30%,
whereas single VPBs were detected in the remaining sub-
jects. Overall, the most common VPB morphologies seen
during exercise testing were characterized in 50% by left
bundle branch block (35% with inferior-axis deviation, 15%
with left-axis deviation) and in 35% by right bundle branch
block (with variable-axis deviation), whereas the 2 mor-
phologies were equally distributed in 15%. Stopping exer-
cise led to the disappearance of VAs in all subjects imme-
diately after or within the first minute of resting. Mean HR
when the VAs disappeared differed significantly from the
mean HR threshold (p  0.03).
For baseline exercise testing on -blocker therapy VAs
isappeared completely in 15% of patients, nonsustained
Ts disappeared, and couplets persisted in 20%. Therapy
as effective in converting polymorphic to monomorphic
atterns in 11 patients (55%). Maximum HR was decreased
ignificantly compared to the test off  blocker, whereas
mean maximum workload did not change significantly. Ar-
rhythmias developed at a lower HR threshold than in the test
off therapy (p  0.03).
For exercise testing on therapy at the last follow-up,
-blocker dosage titration was needed in 10 patients. No
significant differences emerged compared to results of the 2
exercise tests conducted on therapy (Table 1). Nonsustained
VTs did not reappear, ventricular couplets decreased from
20% to 5%, and polymorphic patterns persisted in 30%.
Comparing the first exercise test off therapy to the last on
therapy, 14 patients (70%) responded to therapy. In detail,
in 7 patients with nonsustained VT as the most severe
arrhythmia, this arrhythmia disappeared (p  0.006); in 7
patients with couplets as the most severe arrhythmia, this
arrhythmia disappeared (p  0.006); and in 6 patients with
single VPBs, VPBs persisted throughout follow-up. During
the last exercise test VPBs of left bundle branch block
morphology persisted compared to right bundle branch
block (60% vs 15%, p  0.006). VPBs with left bundle
branch block morphology presented inferior-axis deviation
(45%) or left-axis deviation (15%). Mean HR threshold of
the VAs decreased but not significantly and workload re-
mained unchanged.
During follow-up only 2 patients became symptomatic.
A 52-year-old woman had an implantable cardioverter–defibrillator because of an episode of syncope. A calcium
channel blocker was added to -blocker therapy. No further
implantable cardioverter–defibrillator events or episodes of
syncope were recorded during a 4-year follow-up. A 20-
year-old woman developed syncope while dancing. Beta-
blocker therapy was increased and no nonsustained VT
appeared. Importantly, silent carriers were treated with 
blocker and no VAs were recorded during follow-up.
Discussion
RyR2 mutation carriers frequently have a family history
of sudden death or they may present with effort-induced
syncope or palpitations. Electrocardiogram is usually nor-
mal and late potentials may be present only in a minority of
cases.17–19 Imaging techniques in most cases reveal normal
ndings.2,20 Exercise testing and Holter monitoring may
ften reveal VAs.22,25 Exercise testing is indicated for as-
sessing subjects with known or suspected effort-induced
VAs and ascertaining the efficacy of medical therapy. An-
tiarrhythmic strategies usually consist of high-dose  block-
ers; nadolol and propranolol are generally used.19 The an-
tiarrhythmic effect is caused by an inhibition of the
sympathetic action to  receptors and it may also improve
yR2 function by restoring the balance between phosphor-
lation and dephosphorylation and attenuate the increase of
arcoplasmic reticulum calcium content.2,4,5 Beta-blocker
therapy is associated with lower event rates but usually fails
to completely suppress VAs. Further studies on concomitant
therapies (verapamil, flecainide, implantable cardioverter–
defibrillator, left ventricular sympathetic denervation) are
ongoing.26–29
In this study acebutolol was used; thus it contributes to
further information on therapy for RyR2 mutation carriers.
Furthermore, detailed analysis of arrhythmic patterns with
and without therapy was assessed. Analysis of the first
exercise test off therapy provided interesting information on
features of the VA pattern. VAs occurred when a mean HR
of 132 13 beats/min and a workload of 111  42 W were
reached (Table 1). The first VPB did not show particular
electrocardiographic characteristics. In most patients VAs
appeared with a monomorphic pattern that became poly-
morphic as they continued to exercise. Ventricular bigem-
iny was common. With the increase of HR there was an
exacerbation of VAs; couplets (145  15 beats/min, p 
.05) and nonsustained VTs (158  16 beats/min, p 
.000 01) appeared at a higher HR compared to onset of
As. The low frequency of VT observed could be explained
y the fact that only few patients exceeded their submaxi-
al HR and only 2 patients were index cases. Moreover,
henotypic manifestations may be variable.20,22 All pa-
tients’ VAs disappeared immediately or shortly after they
stopped exercising, implicating the importance of the vagal
reactivation.
The first exercise test on  blocker showed that the mean
HR threshold of VAs decreased significantly (p  0.03). A
similar result was found at the end of follow-up by Haugaa
et al30 using different  blockers. During the last exercise
test the HR threshold decreased but not in a significant
manner and importantly it was not accompanied by an
increase of VA severity. Therapy with  blocker was able to
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level of workload as off therapy, thus not permitting more
complex VAs to develop. Overall, in 20% VAs disappeared
(p  0.04). In 3 patients the decrease in maximum HR
below the personal threshold of VAs could explain why no
VAs occurred. The observation that further titration led to a
decrease of VAs in only 1 more patient could be explained
by the fact that maximum HR did not change significantly,
probably because of intrinsic sympathicomimetic activity.
In addition,  blocker was efficient in decreasing the com-
plexity of the arrhythmic pattern in most patients, inhibiting
the development of nonsustained VT, decreasing couplets
significantly (to 5%), and decreasing polymorphic patterns
(to 25%). Previous observations support the hypothesis that
the -blocker effect is caused by a decrease of maximum
R and additional mechanisms involved in the decrease
f VAs.2,4,5
It is important to emphasize that 3 patients (15%) only
had single monomorphic VPBs that remained monomorphic
in 2 throughout follow-up. The prompt initiation of therapy
does not permit us to predict if more complex arrhythmias
could appear later in the absence of therapy. In these sub-
jects the first exercise test alone could not distinguish idio-
pathic adrenergic VAs from those linked to RyR2 mutations
because the latter were identified by family screening. Di-
agnosis was achieved by analyzing the family history of
sudden death, demonstrating effort-induced polymorphic
VPBs in other family members, and repeating the exercise
test (which revealed a different VPB morphology in 1 sub-
ject). Identifying disease-causing RyR2 mutations through
genetic screening confirms the diagnosis.
It is important to note that -blocker therapy was unable
o modify the arrhythmic pattern in 30% of patients char-
cterized by single VPBs. Although a different type of 
blocker was used in this study, the findings are similar to
data published by Haugaa et al30 who reported no effect of
-blocker therapy in 43% of subjects and that less severe
arrhythmias were not decreased despite the maximum tol-
erated dose of  blocker. The observation that noncomplex
VAs persisted throughout follow-up could be interpreted as
a protective mechanism of  blockers against more severe
arrhythmias. Further studies in larger series are needed to
establish whether some  blockers have greater efficacy
than others and if their efficacy depends on the specific
mutation on the RyR2 gene and severity of the arrhythmic
pattern.
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